TheraRadar
Data updated: May 26, 2026

LOTEMAX SM (loteprednol etabonate)

Pain Approved 2019-02-22

Lotemax SM is a corticosteroid gel used for patients recovering from eye surgery. It helps patients with the inflammation and pain that typically occur after these procedures. This medication is prescribed to manage the eye's natural response to surgical trauma and support a smoother recovery.

Source: FDA Label • BAUSCH AND LOMB INC

How LOTEMAX SM Works

This medication works by inhibiting the body's inflammatory response to surgical triggers. It binds to and activates glucocorticoid receptors, which helps reduce swelling, capillary dilation, and the formation of scar tissue. Additionally, it is thought to block the production of prostaglandins to further decrease inflammation and pain.

1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2019-02-22
Patent Cliff
2036

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OPHTHALMIC
Dosage Forms
GEL

Companies

Active Ingredient: LOTEPREDNOL ETABONATE

LOTEMAX SM Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2019 to 2019
Feb 2019 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What LOTEMAX SM Treats

2 indications

LOTEMAX SM is approved for 2 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Inflammation
  • Pain
Source: FDA Label

LOTEMAX SM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 16 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LOTEMAX SM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACUVAIL
KETOROLAC TROMETHAMINE
2 shared
AbbVie
Shared indications:
BYQLOVI
CLOBETASOL PROPIONATE
2 shared
HARROW EYE
Shared indications:
DIFLUPREDNATE
DIFLUPREDNATE
2 shared
Viatris
Shared indications:
📋

Clinical Trial Registry

12 trials
Trial Sponsor ID Phase Status Title
NCT04555694 results posted TC-2020-DexRes Ph 4 completed Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
NCT01437982 628 Ph 4 completed A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
NCT01443442 results posted MAC-06-11 Ph 4 completed Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
NCT01475643 results posted 670 Ph 3 completed Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
NCT03098953 881 Ph 1 completed Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
NCT01853696 results posted 2013-0424 Ph 4 completed Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
NCT00699153 results posted 526 Ph 3 completed Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT00705159 results posted 550 Ph 4 completed Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
NCT02028312 CEI.HER-002 Ph 4 withdrawn A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
NCT01724892 othana001 Ph 4 completed Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing
NCT01060072 results posted 577 Ph 3 completed Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01010633 results posted 576 Ph 3 completed Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LOTEMAX SM FDA Label Details

Indications & Usage

FDA Label (PDF)

LOTEMAX SM is indicated for the treatment of Inflammation; Pain.

View full patent landscape →
2 OB patents · 1 families · 55 international docs across 15 countries

LOTEMAX SM Patents & Exclusivity

Latest Patent: Dec 2036

Patents (3 active)

US10596107 Expires Dec 23, 2036
US11534395 Expires Jan 26, 2036
US12589069 Expires Jan 26, 2036
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for LOTEMAX SM

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2036
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.